Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.

Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A; Phase 2 Trial NP001 Investigators.

Neurol Neuroimmunol Neuroinflamm. 2015 Apr 9;2(3):e100. doi: 10.1212/NXI.0000000000000100. eCollection 2015 Jun.

2.

Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history.

Mandal DM, Sartor O, Halton SL, Mercante DE, Bailey-Wilson JE, Rayford W.

Prostate Cancer Prostatic Dis. 2008;11(3):274-9. doi: 10.1038/pcan.2008.5. Epub 2008 Feb 12.

Supplemental Content

Loading ...
Support Center